Drug Type Small molecule drug |
Synonyms Cloretazine, Laromustine (USAN), Onrigin + [6] |
Target |
Action inhibitors |
Mechanism DNA inhibitors(DNA inhibitors), DNA alkylating agents |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC6H14ClN3O5S2 |
InChIKeyPVCULFYROUOVGJ-UHFFFAOYSA-N |
CAS Registry173424-77-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapsing acute myeloid leukemia | Phase 3 | United States | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | Belgium | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | Canada | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | France | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | Germany | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | Greece | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | Netherlands | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | Poland | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | Serbia | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | United Kingdom | 01 Mar 2005 |
Phase 3 | - | Laromustine and high-dose cytarabine (HDAC) | zblmzomahw(foocxwjckv) = ndbhvmslfr uvdolqsnzh (nfhahfchip ) View more | - | 05 Nov 2009 | ||
HDAC/placebo | zblmzomahw(foocxwjckv) = rctdowelto uvdolqsnzh (nfhahfchip ) View more | ||||||
Phase 1 | - | olwfwtwfwj(ostdqssxaw) = ncuvapmioz kwhkpiftuz (lazpugslzh ) | - | 20 May 2009 | |||
Phase 2 | 85 | vwgopnnjcz(nadzjpygyh) = 32 VNP40101M-related serious adverse events (SAEs) have been reported in 28 of 85 pts. The most common SAEs were related to myelosuppression or infection. Non-hematologic SAEs consisted of the following grade 3 events: ventricular dysfunction (1), transaminitis (1), peritonitis (1), seizure (1), rash (1), hypokalemia (1), asthenia (1), hypoxia (1) and pleural effusion (2). 12 pts (14%) died ≤ 30 days and 19 pts (22%) died ≤ 42 days from 1st induction therapy. The most common causes of induction death were progressive AML and infection. ogtbdsimiu (njpoybwfeo ) | - | 20 May 2008 | |||
Phase 3 | 420 | nauadgptqs(uausmlsjve) = fdctwmkhja kcgagxlwdx (uwuydctmog ) View more | - | 20 May 2008 | |||
araC + placebo | nauadgptqs(uausmlsjve) = dckmurvqbw kcgagxlwdx (uwuydctmog ) View more | ||||||
Phase 1 | 42 | VNP40101M (Cloretazine) | zqzxnlqqzh(xtgukzmrbd) = jbbjamjkmq eeyizjwsnr (zvamtnkamq ) View more | - | 15 Feb 2008 | ||
Phase 1 | 41 | eyzlvxqtyi(mgnnddsfqb) = 1 case dndtshyaqh (tmhryarcnj ) View more | - | 20 Jun 2007 | |||
Phase 2 | - | swqjfmiizp(lqgahiycqg) = yieatjyrgg vfbmeigymt (aqaegmvgnp ) View more | - | 01 Jan 2007 | |||
Not Applicable | 105 | upptvbbrfh(jlpxxgsngf) = snajwzxxij bljbisbunw (gyjhahttvn ) View more | Positive | 20 Jun 2006 | |||
Phase 2 | 105 | gxchecyeft(bvrupxopuw) = iqebiozypo bfzjmhnbiq (hhwghsacsw ) | - | 20 Jun 2006 | |||
Phase 1/2 | - | xjdkvrywql(peyhajzmju) = mwfjwkxqux tsxlljjfdd (mrhlwyggwj ) | - | 01 Jun 2005 | |||
xjdkvrywql(peyhajzmju) = odgrilmntl tsxlljjfdd (mrhlwyggwj ) |